State litigation guide · Florida

Elmiron Vision Loss Lawsuit in Florida

Time limits apply in Florida. Find out if you still qualify.

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

People's Justice Research TeamUpdated June 25, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Statute of limitations — Florida

Florida Statute § 95.11(3)(a) provides a 2-year statute of limitations for personal injury claims including pharmaceutical product liability (reduced from 4 years by 2023 tort reform). The discovery rule applies — the clock starts when the plaintiff discovers or reasonably should have discovered Elmiron caused their vision damage. Florida has a 12-year statute of repose under § 95.031(2)(b).

2 years from discovery of Elmiron-related vision injury

Filing venue

Where to File in Florida

Federal Elmiron cases from Florida are transferred to the MDL in the District of New Jersey (MDL No. 2973). Florida state court claims may proceed separately in Miami-Dade, Broward, Hillsborough, or Palm Beach County circuit courts. Florida's 2023 tort reform shortened the statute of limitations from 4 to 2 years, which may catch some plaintiffs off guard. Florida courts apply the Daubert standard for expert testimony. The state's large elderly population and high IC diagnosis rates make it one of the top-filing states in the MDL.

Florida data

Exposure in Florida

Florida population — third-largest state with a disproportionately high rate of interstitial cystitis due to older demographics

22.6 million

Source: U.S. Census Bureau 2024

The specific retinal condition linked to Elmiron — characterized by dark spots on the macula that can cause blurred vision, difficulty reading, and adaptation problems in dim lighting

Pigmentary maculopathy

Source: American Academy of Ophthalmology

Year Elmiron was originally FDA-approved — patients took the drug for decades before the retinal toxicity link was identified by Emory University researchers in 2018

1996

Source: FDA drug approval records

Keep reading